Endocrine Abstracts

Background: The diagnosis of neuroendocrine tumor disease has been tardy due to a lack of sensitive, noninvasive technology to facilitate identification. In the 1960’s, diagnosis required tumor tissue attained by surgery or biopsy. Identification was by histopathology and immunohistochemistry (1975). Acquisition of information was limited by the morbidity of invasive strategies, inability to reassess and interpretation was user-dependent with low kappa values. The introdu...

Background: The NETest, a neuroendocrine multigene transcript ‘liquid biopsy’, is a novel biomarker for GEP-NETs. Current biomarkers are monoanalyte amines or peptides whereas the NETest is a multianalyte signature providing molecular biological information pertinent to clinical disease.Aim: Independently validate the utility of the NETest for the diagnosis of GEP-NETs and identification of disease progression.Material an...

Background: There are no effective blood biomarkers for bronchopulmonary carcinoids (BPC). We examined the utility of a neuroendocrine multigene transcript ‘liquid biopsy’ (NETest) in bronchopulmonary carcinoids (BPC) for diagnosis and monitoring of disease status.Aim: To independently validate the utility of the NETest in diagnosis and management of BPC in a prospective multicenter, multinational blinded study.Material a...

Background: Small-bowel neuroendocrine tumours (SB-NET) commonly metastasise despite most being low grade. The NET nomogram developed, estimates 5- and 10-year survival in SB-NET by allocating scores for 15 clinicopathological parameters. We comparatively evaluated the prognostic power of this nomogram, the WHO/ENETS grading and AJCC/UICC staging systems.Methods: Patients with histologically-confirmed SB-NET were identified from databases at two tertiary...

Introduction: There is a substantial unmet clinical need for an accurate and effective blood biomarker for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Current monoanalyte biomarkers are ineffective. The NETest, a novel multianalyte signature, provides molecular information relevant to disease biology. We therefore evaluated, under real-world conditions, the clinical utility of the NETest as a liquid biopsy in GEP-NETs.Aim(s): Independently ...

Background: There is currently no effective blood biomarker for lung neuroendocrine neoplasia diagnosis and management. We describe the clinical utility of a 51 neuroendocrine-specific gene expression set in blood to diagnose bronchopulmonary neuroendocrine tumors (BPNETs) and define their clinical status.Methods: The discovery set included BPNETs (n=154) and controls (n=90), randomly assigned (1:1) to a test and validation set. Specifi...

Background: Neuroendocrine tumours of the appendix (ANET) are relatively indolent tumours typically identified incidentally at surgery for suspected appendicitis. The role of right hemicolectomy (RH) for tumours with ‘high risk’ features is debated. We compared the management of ANET at three centres against ENETS criteria for therapy selection.Methods: Retrospective review of all patients diagnosed with ANET at three tertiary centres. Patients...

Introduction: Novel molecular analytes are needed in small bowel neuroendocrine tumours (SBNETs) to better determine disease aggressiveness and predict treatment response.Aim of the study: To profile the global miRNome of SBNETs, and identify microRNAs (miRNAs) involved in tumour progression for use as potential biomarkers.Material and methods: Two independent miRNA profiling experiments were performed (n=90), including pr...

Introduction: Surgery is the only cure for neuroendocrine tumor (NET) disease. R0 resection is critical for successful tumor resection. Early detection of residual disease is key for optimal management. Both imaging and current biomarkers have intrinsic limitations and are largely ineffective up to 3 months post-surgery. NETest, a multigene blood biomarker test, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scor...